在达帕格利弗洛辛影响慢性期慢性心力衰竭中慢性期功能后,估计的淋巴细胞过率的初始下降
Raisa Ogata1, Takato Kotaki1, Kozue Tanaka1
1Department of Pharmacy, Kurume University Hospital, Kurume 830-0011, Japan.
Journal of clinical medicine
|August 14, 2025
概括
在治疗慢性心力衰竭 (CHF) 的达帕格利弗洛辛期间,估计的淋巴膜过率 (eGFR) 的初始下降与老年,高血压和糖尿病有关. 这种下降可能表明长期的功能变化.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 达帕格利弗洛辛是一种SGLT2抑制剂,有利于慢性心力衰竭 (CHF) 患者.
- 在SGLT2抑制剂治疗的早期,估计膜过率 (eGFR) 的初始下降是常见的.
- 了解初始下降的因素和影响对于CHF管理至关重要.
研究的目的:
- 为了确定在CHF患者的达帕格利弗洛辛治疗期间与eGFR初始下降相关的因素.
- 评估初始浸泡对长期功能的影响.
- 探索初始水作为脏保护作用的潜在预测因素.
主要方法:
- 对123名连续CHF患者开始服用达帕格利弗洛辛的回顾性分析.
- 初始入的定义:在两周内,eGFR下降≥5mL/min/1.73m2.
- 基线临床特征和功能数据的分析.
主要成果:
- 高龄,高血压,糖尿病和更高的基线eGFR是最初下降的风险因素.
- 年龄和初始下降的存在与6个月和1年的eGFR变化相关.
- 患有初始下降的患者随着时间的推移显示出持续的eGFR下降.
结论:
- 最初的下降在患有高血压和/或糖尿病的老年CHF患者中更为普遍.
- 最初的下降可能会影响DAPAGLIFLOZIN在CHF患者的长期结局.
- 最初的浸泡可以作为达帕格利弗洛辛长期保护功效的早期指标.
相关概念视频
01:11Renal Failure: Dose Adjustments
155
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
155
01:29Acute Kidney Injury III: Clinical Manifestations
94
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
94
01:22Heart Failure Drugs: Diuretics
484
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
484
01:17Factors Affecting Renal Clearance: Renal Impairment
160
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
160
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
508
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
508